APA (7th ed.) Citation

Heublein, S., Egger, M., Zhu, J., Berger, L., Mayr, D., Schindlbeck, C., . . . Ditsch, N. (2020). Evaluation of the anti-Thomsen-Friedenreich antibodies Nemod-TF1 and Nemod-TF2 as prognostic markers in breast cancer. Breast cancer research and treatment, 179(3), . https://doi.org/10.1007/s10549-019-05503-6

Chicago Style (17th ed.) Citation

Heublein, Sabine, et al. "Evaluation of the Anti-Thomsen-Friedenreich Antibodies Nemod-TF1 and Nemod-TF2 as Prognostic Markers in Breast Cancer." Breast Cancer Research and Treatment 179, no. 3 (2020). https://doi.org/10.1007/s10549-019-05503-6.

MLA (9th ed.) Citation

Heublein, Sabine, et al. "Evaluation of the Anti-Thomsen-Friedenreich Antibodies Nemod-TF1 and Nemod-TF2 as Prognostic Markers in Breast Cancer." Breast Cancer Research and Treatment, vol. 179, no. 3, 2020, https://doi.org/10.1007/s10549-019-05503-6.